In detail, these clinical studies showed that lomeguatrib exhibits minimal toxicity and an extremely high suppressing effect on MGMT in leukemia [209,228,229], melanoma [230,231,232], and colorectal cancer [233]. The gene discussed is MGMT; the disease is leukemia.